Summary

Eligibility
for females ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around
Principal Investigator
by Gottfried E. Konecny, MD (ucla)
Headshot of Gottfried E. Konecny
Gottfried E. Konecny

Description

Summary

This is a randomized, phase 1b study to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of sovilnesib at different dose levels to establish the Recommended Phase 2 Dose (RP2D) of sovilnesib in subjects with high grade serous ovarian cancer (HGSOC).

Official Title

A Phase 1b Dose Optimization Study of Sovilnesib (an Oral KIF18A Inhibitor) in Subjects with Advanced High Grade Serous Ovarian Cancer

Details

Keywords

High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Chromosomal Instability, KIF18A Inhibitor, Fallopian Tube Neoplasms, Serous Cystadenocarcinoma, Sovilnesib

Eligibility

Locations

  • UCLA accepting new patients
    Los Angeles California 90095 United States
  • Hoag Memorial Hospital accepting new patients
    Newport Beach California 92663 United States

Lead Scientist at University of California Health

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Volastra Therapeutics, Inc.
ID
NCT06084416
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 120 study participants
Last Updated